Luo Tiantian, Wang Ju, Hao Shilei, Guo Tingwang, Ren Peng, Cheng Zhongjun, Gao Feiyan, Gong Yuhua, Wang Bochu
Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400030, China.
Curr Pharm Des. 2017;23(15):2258-2267. doi: 10.2174/1381612822666161025155058.
Stroke remains the second commonest cause of death and leading cause of adult disability worldwide. Ischemic events account for nearly 85% of all strokes, and hemorrhages account for nearly 15%. Stroke intervention and recovery have been identified as the important factors in the functional outcome of patients with completed stroke. However, the only FDA approved treatment for ischemic strokes is tissue plasminogen activator, and no effective targeted therapy for hemorrhagic stroke exists yet.
The goal of this work is to review the brain drug delivery systems (BDDS) used for stroke intervention and recovery.
Many novel BDDS have been developed for the use of stroke intervention and recovery, including nanoparticles, hydrogels, fibers, liposomes, and so on, which could improve the permeability of blood-brainbarrier (BBB), short half-life, stability in vivo, and reduce adverse effects of drugs.
Combined with new drug targets in the treatment of stroke, BDDS will provide more effective therapeutics for stroke intervention and recovery.
中风仍然是全球第二大常见死因和成人残疾的主要原因。缺血性事件占所有中风的近85%，出血性中风占近15%。中风干预和恢复已被确定为中风患者功能结局的重要因素。然而，美国食品药品监督管理局（FDA）批准的唯一用于缺血性中风的治疗方法是组织纤溶酶原激活剂，目前尚无针对出血性中风的有效靶向治疗方法。
这项工作的目标是回顾用于中风干预和恢复的脑药物递送系统（BDDS）。
已经开发了许多用于中风干预和恢复的新型BDDS，包括纳米颗粒、水凝胶、纤维、脂质体等，这些可以提高血脑屏障（BBB）的通透性、缩短半衰期、提高体内稳定性，并减少药物的不良反应。
结合中风治疗中的新药物靶点，BDDS将为中风干预和恢复提供更有效的治疗方法。
